Drugs / Lutetium Lu 177 PSMA-10.1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06105918 | Nov 2023 → Apr 2028 expected | prostate adenocarcinoma | Emory University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lutetium Lu 177 PSMA-10.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06105918 ↗ |
| Route | Intravenous | “177Lu-rhPSMA-10.1 intravenously (IV) on study” NCT06105918 ↗ |